Helix BioPharma Announces Positive Interim Results From Its Ongoing Phase II Pharmacokinetic Clinical Study Of Topical Interferon Alpha-2b
Helix BioPharma Corp. (TSX, FSE: HBP; Pink Sheets: HXBPF) announced that the first ten patients that have been enrolled in its Phase II pharmacokinetic study of Topical Interferon Alpha-2b in patients with low-grade cervical lesions have completed the pharmacokinetic primary endpoint analyses with positive findings…
This entry was posted on Saturday, February 13th, 2010 at 1:00 am and is filed under Womens' Health. You can follow any responses to this entry through the RSS 2.0 feed. You can skip to the end and leave a response. Pinging is currently not allowed.